Clinical TrialsSearch results
Number of results: 255
Other
- Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutations
- non-small cell lung cancer
- Hokkaido Lung Cancer Clinical Study Group
- 2005-09-12
Recruiting
- Multicenter Study to Evaluate the Usefulness of TCR Repertoire as a Prognostic Marker in Postoperative Adjuvant Atezolizumab for Non-Small Cell Lung Cancer
- non-small cell lung cancer
- Suzuki Hiroyuki
- 2023-10-31
Other
- Randomized phase III study of Standard CHOP(S-CHOP) versus Biweekly CHOP(Bi-CHOP) in aggressive Non-Hodgkin's Lymphoma(JCOG9809)
- Non-Hodgkin's lymphoma
- Japan Clinical Oncology Group(JCOG)
- 2005-08-04
Other
- Randomized phase II trial of Carboplatin/Gemcitabine versus Cisplatin/Gemcitabine for the patient with completely resected pathological stage IB-IIIA of Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Hokkaido Lung Cancer Clinical Study Group
- 2007-11-29
Other
- A Phase II study of induction chemotherapy S-1 and CDDP in patients with FDG-PET positive N2 disease of non-small cell lung cancer.
- Non small cell lung cancer
- Fukushima Medical University
- 2006-04-01
Recruiting
- Phase II trial using imatinib combined with chemotherapy for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)
- Newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)
- Japan Adult Leukemia Study Group
- 2008-07-07
Completed
- A Clinical, Imaging and Biomarker Study in Neuromyelitis Optica Spectrum Disorder (NMOSD) with Satralizumab as an Intervention
- Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Regine Buffels
- 2022-06-25
Other
- A late phase II study of multidisciplinary approach to establish standard treatment for advanced neuroblastoma
- neuroblastoma
- Japan Neuroblastoma Study Group
- 2008-02-20
Other
- 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
- Neuroblastoma
- Tomita Koji
- 2020-10-21
Recruiting
- Roll-over study for patients who have completed a prior Novartis-sponsored sabatolimab (MBG453) study and are judged by the investigator to benefit from continued treatment with sabatolimab.
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
- Yamauchi Kyosuke
- 2024-06-27